Appropriate Use Criteria for Prostate-Specific Membrane Antigen (PSMA) PET Imaging

To guide referring and imaging physicians to use PSMA PET imaging agents appropriately, The Society of Nuclear Medicine and Molecular Imaging (SNMMI), American College of Nuclear Medicine (ACNM), American Urological Association (AUA), Australia and New Zealand Society of Nuclear Medicine (ANZSNM), American Society of Clinical Oncology (ASCO), European Association of Nuclear Medicine (EANM), and American College of Physicians (ACP) worked collaboratively to develop criteria for the appropriate use of this new imaging technology.

SNMMI assembled an autonomous PSMA PET Imaging Workgroup to represent a multidisciplinary panel of health care providers with substantive knowledge in the use of nuclear medicine procedures in prostate cancer imaging to review the scientific literature and develop consensus recommendations for the clinical use of this technology. The Oregon Health Science University's (OHSU) Evidence-based Practice Center (EPC) conducted a systematic review of existing evidence based on the scope and parameters the PSMA PET Imaging Workgroup put together, The systematic review was used to make their recommendations for clinical use.

Click here to view AUC for Prostate-Specific Membrane Antigen (PSMA) PET Imaging 

To view the development process, please click the following link: SNMMI AUC Development Process.